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Introduction {#sec001}
============

Aristolochic acid nephropathy (AAN) was first introduced in 1993 \[[@pone.0227838.ref001]\]. After the Belgian women ingested slimming pills containing aristolochic acid (AA), their renal function dramatically decreased and managed by dialysis. The feature of AAN is rapid progression into interstitial renal fibrosis and end-stage renal disease \[[@pone.0227838.ref001], [@pone.0227838.ref002]\]. AA is extracted from the *Aristolochiaceae* species and was used for anti-inflammatory activities in traditional medicine. AA is a mixture of 8-methoxy-6-nitrophenanthro-(3,4-D)-1,3-dioxolo-5-carboxylic acid (aristolochic acid I \[AAI\]) and its 8-demethoxylated form (aristolochic acid II \[AAII\]) \[[@pone.0227838.ref003]\]. AAI shows stronger nephrotoxicity than AAII in AAN because of the *O*-methoxy group at position C-8 of the nitrophenanthrene ring \[[@pone.0227838.ref004]\]. This structure of AAI facilitates AA interactions with DNA, and this AA-DNA adduct leads to cytotoxicity and carcinogenicity. A recent study indicates that AA-induced upper tract urothelial cancer is related to p38 and extracellular signal regulated kinases (ERK) sub-pathways \[[@pone.0227838.ref005]\]. Despite prohibition of AA-containing herbs, patients are still suffering from AAN \[[@pone.0227838.ref006]\]. Vanherweghem *et al*. successfully treated AAN with prednisolone, because AAN is thought to be related to the immune response, such as infiltration of immune cells into the renal cortex \[[@pone.0227838.ref007]\]. Recently, Ma *et al*. showed that low-dose prednisone (0.5 mg/kg) is effective at slowing the progression of AAN via the suppression of monocyte chemoattractant protein-1 (MCP-1) and transforming growth factor-β (TGF-β) activities \[[@pone.0227838.ref008]\].

Prednisolone, one of the glucocorticoids, acts as endogenous cortisol that is released from the hypothalamic-pituitary-adrenal (HPA) axis, particularly in the case of stress or injury \[[@pone.0227838.ref009]\]. Prednisolone fights inflammation via the regulation of tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) etc, thus, widely applied to treating various inflammation diseases or states, such as allergies, asthma, dermatitis, rheumatic disorders, systemic lupus erythematosus, and autoimmune disorders\[[@pone.0227838.ref010]--[@pone.0227838.ref012]\]. Recently, Baudoux *et al*. demonstrated that cluster of differentiation CD4^+^ and CD8^+^ T-cells regulate immune responses in AA-induced acute tubular necrosis \[[@pone.0227838.ref013]\]. However, the mechanism of prednisolone treatment for AAN is still unclear. Moreover, prednisolone plays an important role in glucose homeostasis, but the relationship between prednisolone and glycolysis, including the impact of methylglyoxal, a by-product of glycolysis, has never been studied. The proteomics study with fluorogenic derivatization-liquid chromatography/tandem mass spectrometry (FD-LC-MS/MS) was introduced in 2004 \[[@pone.0227838.ref014], [@pone.0227838.ref015]\]. This FD-LC-MS/MS method was widely applied to screening proteins in cell lines \[[@pone.0227838.ref016]\], rat \[[@pone.0227838.ref017]\], mouse models \[[@pone.0227838.ref018]\]. Therefore, the aim of this study was to explore the effect of prednisolone on changes in glycolysis-related protein expression using FD-LC-MS/MS method in the AAN mice model and clarify the pharmacological mechanisms of prednisolone in AAN model.

Materials and methods {#sec002}
=====================

Animal experiments {#sec003}
------------------

All of the animal use protocols were approved by the Animal Care and Use Committee/Panel of Taipei Medical University (IACUC Approval No: LAC-2013-0282), and the performance was complied with the relevant regulations. The AAN model and experiments protocols were followed previous studies. Six-week‐old female C3H/He mice were randomly divided into three groups: normal (N), aristolochic acid (AA), and aristolochic acid + prednisolone (AA+P) groups (n = 10 each group). The AA and AA+P group mice received *ad libitum* access to 3.0 μg/mL of AA-distilled water (0.5 mg/kg/day) orally for 56 days according to the previous study \[[@pone.0227838.ref018]\]. For the next 14 days, AA+P group were gavage fed prednisolone (2 mg/kg/day), and AA group were gavage administrated water, respectively. The N group mice drank water during the study period. Mouse urine was collected within 12 hours on days 0, 7, and 14 via a metabolic cage (Tokiwa Chemical Industries Co. Ltd, Japan) \[[@pone.0227838.ref018]\]. All the mice were sacrificed on day 14. All of the harvested urine, kidney tissue, and blood were stored at -80°C before analysis \[[@pone.0227838.ref018]--[@pone.0227838.ref020]\].

Biochemical assays {#sec004}
------------------

All biochemical parameters from each of the 30 mice were measured. Blood urea nitrogen (BUN) was determined using a Beckman blood urea nitrogen kit, and serum creatinine (Scr) was measured with a DxC 600 chemistry analyzer (Beckman Coulter, IN USA) \[[@pone.0227838.ref018]\]. The fluorometric method was used to determine the activity of urinary NAG, which was defined as the production of 4-MU from 4-MU-NAG in 100 mM citrate buffer (pH 4.6--5.0) within 15 minutes, and the activity was measured at 370 nm/460 nm (excitation/emission wavelength) \[[@pone.0227838.ref021]\]. Urinary protein was determined via the Bradford method \[[@pone.0227838.ref022]\]. All the work of this study was shown in [Fig 1](#pone.0227838.g001){ref-type="fig"}.

![Flow chart for the current study.\
Analysis of kidney tissues: (1) Paraffin-embedded kidney sections were stained with periodic acid--Schiff (PAS) stain and Masson trichrome stain; the cryostat kidney sections underwent immunofluorescence studies in order to determine transforming TGF-β, matrix metallopeptidase 9 (MMP9), and human growth factor (HGF); (2) The kidney samples homogenized with CHAPS ~(aq)~ were used for the proteomics study. Before analysis, the proteins were quantitated with the bicinchoninic acid (BCA) protein assay. The kidney sample proteins were derivatized with 4-\[2-(dimethylamino)ethylaminosulfonyl\]-7-chloro-,1,3-benzoxadiazole\] (DAABD-Cl) and then separated by fluorescence detection-high-performance liquid chromatography (FD-HPLC). The altered peak fractions were compared and collected, digested with trypsin, and analyzed by liquid chromatography--tandem mass spectrometry (LC-MS/MS). Finally, the altered proteins were identified with the MASCOT software. (3) Immunoblotting analyses for GLO1, TPI, and aldolase B protein expressions were performed to confirm proteomic study findings. Blood samples were collected to analyze BUN and serum creatinine (Scr). Urine samples were collected to analyze urinary NAG activity and protein, methylglyoxal, and D-lactate levels. Aldolase B, fructose-bisphosphate aldolase B; CHAPs ~(aq)~; DAABD-Cl; FD-HPLC, high performance liquid chromatography with fluorescence detection; GLO1, glyoxalase 1; LC-MS/MS, liquid chromatography-tandem mass spectrometry; TPI, triosephosphate isomerase.](pone.0227838.g001){#pone.0227838.g001}

Histological examination {#sec005}
------------------------

All of the kidneys from the 30 mice were embedded with paraffin, and the sections were sliced into 4 to 5 μm sections \[[@pone.0227838.ref018], [@pone.0227838.ref019]\]. The kidney sections were stained with periodic acid--Schiff (PAS) (395B, Sigma-Aldrich, Inc., MO, USA) and Masson trichrome stain (HT15, Sigma-Aldrich, Inc., MO, USA) according to the manufacturers' instructions.

Immunofluorescence study {#sec006}
------------------------

Samples from kidneys from the 30 mice were prepared for immunofluorescence study which were performed previously \[[@pone.0227838.ref018]\]. Briefly, the cryostat sections (4 μm) were incubated with rabbit polyclonal transforming growth factor-beta 1 (TGF-β) antibody (21898-1-AP, Proteintech Group, Inc, IL, USA), rabbit polyclonal matrix metallopeptidase 9 (MMP9) (N-Terminal) antibody (10375-2-AP, Proteintech Group, Inc, IL, USA), or rabbit polyclonal anti-human growth factor (HGF) antibody (ab83760, Abcam, OR, USA) for 30 min at room temperature, and all the primary antibodies were diluted with phosphate buffered saline (PBS) at 1:100. The sections were washed with PBS for three times. Under dark environment, the sections were reacted with tetramethyl rhodamine isothiocyanate (TRITC)-labeled anti-rabbit IgG (T6778, Sigma-Aldrich, Inc., MO, USA) and washed with PBS for three times. The images were de‐convoluted and processed using a laser confocal microscope, Olympus FV500 (Tokyo, Japan). The positive area (red) was quantified using FluoView Olympus version 4.0 (Tokyo, Japan) \[[@pone.0227838.ref018]\].

Proteomics study {#sec007}
----------------

### Sample preparation {#sec008}

Six kidney samples from each group (n = 10) were selected for the proteomics study. First, about 50 mg of kidney tissue was homogenized with 300 μL of 10 mM 3-\[(3-cholamidopropyl) dimethylammonio\] propanesulfonic acid~(aq)~ (CHAPS~(aq)~) and measured the amount of protein using BCA Pierce^™^ BCA Protein Assay Kit \[[@pone.0227838.ref017], [@pone.0227838.ref018]\].

Each of the homogenate was diluted into 4 mg/mL. The 10 μL of homogenate was reacted with 20 μL of 10 mM ethylenediaminetetraacetic acid disodium salt (EDTA·2Na), 20 μL of 50 mM CHAPS~(aq)~, 20 μL of 2.5 mM tris (2‐carboxyethyl) phosphine, 25 μL of 8 M guanidine buffer (pH 8.5), and 5 μL of 140 mM 7‐chloro‐*N*‐\[2‐(dimethylamino)ethyl\]‐2,1,3‐benzoxadiazole‐4‐sulfonamide (DAABD‐Cl) in acetonitrile (MeCN). Second, the mixture was derivatized under 40°C for 10 min and terminated with 3 μL of 20% trifluoroacetic acid (TFA).

### FD‐HPLC conditions for protein separation and quantification {#sec009}

Forty microliters of the reaction mixture (15.5 μg protein) were injected into the FD‐HPLC at a flow rate of 0.55 mL/min and separated on with the IMTAKT WX‐RP column (250 × 4.6 mm, 3 μm particle size, Imtakt Co., Kyoto, Japan) at 60°C. Mobile phase A (H~2~O/MeCN/isopropanol/TFA = 90/9/1/0.15), mobile phase B (H~2~O/MeCN/isopropanol/TFA = 30/69/1/0.15), and mobile phase C (H~2~O/MeCN/isopropanol/TFA = 95/4/1/0.20) were used \[[@pone.0227838.ref017], [@pone.0227838.ref018]\]. The gradient program is described in [S1 Table](#pone.0227838.s001){ref-type="supplementary-material"}. The fraction was monitored at 505 nm (excitation wavelength: 395 nm). Based on the specific retention time of the derivatives, all of the corresponding peaks of the proteins were quantified by peak height. The FD-HPLC chromatograms of N, AA and AA+P groups were compared by each peak height using Kruskal-Wallis test, and only the altered peak fractions among three groups were manually collected according to the chromatograms for protein identifications.

### Identification of DAABD-derivatized proteins {#sec010}

Each of the collected peak fractions (altered peaks among three groups) was concentrated to 5 μL under the condition of reduced pressure. In order to identify the DAABD-derivatized proteins by using liquid chromatography tandem-mass spectrometry (LC-MS/MS), the residue from the above step was digested with 20 μL of 50 mM NH~4~HCO~3~ (pH 7.8), 2.5 μL of 10 mM CaCl~2~, and 2.5 μL trypsin for 2 h at 37°C. Six microliters of the peptide mixture was directly subjected to LC-MS/MS (Agilent, CA, USA), including NanoLC Agilent 1200, HPLC Agilent 1100, and API 4000Q TRAP. Each sample was loaded onto a nanoprecolumn (Zorbax 300SB-C18; 5 x 0.3mm I.D.; Agilent) in the injection loop and eluted with 0.10% TFA in 2.0% MeCN at 30 mL/min using the Agilent 1100 pump. Then, the peptides were separated in a C18 NanoEase column (75 μm × 100 mm, 3.5 μm particle size; Waters Corporation, CA, USA) at a flow rate of 0.2 μL/min. The mobile phases included mobile phase A (H~2~O/formic acid \[FA\] = 99.9/0.1) and mobile phase B (MeCN/FA = 99.9/0.1), and the gradient elusion was performed for 45 min: 1.0% mobile phase B at the beginning; 50% mobile phase B at 31 min; 85% mobile phase B at 33 min; held for 3 min; and returned to 1% mobile phase B at 37 min. All of the peptides were sprayed into the mass spectrometry (MS; API 4000Q TRAP; Agilent) via a distal coated fused‐silica needle (75 μm tube i.d., 15 μm tip i.d., PicoTip^™^ Emitter, New Objective, MA, USA). One‐second MS/MS scans were conducted on each precursor ion. The detected ions with m/z between 350 and 1250 were fragmented with capillary energies ranging from 1300--2500 V, and the temperature of the interface heater was set at 150°C.

These collected peptides were identified using MASCOT according to previously published methods \[[@pone.0227838.ref017], [@pone.0227838.ref018]\]. MASCOT version 2.2 against the National Center for Biotechnology Information was used to analyze the data. The searching parameters of MASCOT were set as the following: taxonomy: mouse; enzyme: trypsin; allowing less than one missed cleavage peptide; peptide charge: 1+, 2+, 3+; variable modification: DAABD-thiol reside of cysteine. The peptide tolerance was set at 1.2 Da, and mass tolerance for the MS and the tandem MS ions were set at 0.6 Da. Under the situation, MASCOT scores which were higher than 45 were counted as valid peptides. If there were many proteins which shared found peptides, the protein that had the highest score was determined.

Immunoblotting analysis {#sec011}
-----------------------

Six kidney samples from each group (n = 10) were selected to perform immunoblotting analysis.Ten microgram of sample proteins of renal homogenate was loaded into each lane and separated on 12% sodium dodecyl sulfate-polyacrylamide gels using an SDS-PAGE system \[[@pone.0227838.ref018]\]. The proteins on the gels were transferred onto nitrocellulose membranes. Antibodies against glyoxalase 1 (GLO1; GTX105792, GeneTex, Irvine, CA, USA), β‐actin (20536--1‐AP, Proteintech, Rosemont,IL, USA), fructose-bisphosphate aldolase B (aldolase B, GTX101363, GeneTex, Irvine, CA, USA), triosephosphate isomerase (TPI, GTX104618, Irvine, CA, USA), and Goat anti-rabbit IgG (H+L), HRP conjugate (SA00001-2, Rosemont,IL, USA) were used at a dilution of 1:1000, 1:2000, 1:3000, 1:3000, and 1:4000, respectively. The signals corresponding to the bands of GLO1 and β‐actin were measured by the TOOL Sensitive ECL kit. ImageJ was used to quantify the intensity of the bands. The relative GLO1 levels were defined as the ratio of GLO1 to β‐actin intensity. All of the information of antibody was described in [S3 Table](#pone.0227838.s003){ref-type="supplementary-material"}.

Determination of urinary amount of methylglyoxal {#sec012}
------------------------------------------------

Urinary methylglyoxal amount from all of the mice were determined. The level of urinary methylglyoxal was determined by FD-HPLC according to a previously published method \[[@pone.0227838.ref020], [@pone.0227838.ref023]--[@pone.0227838.ref025]\]. In short, the methylglyoxal was incubated with 6-diamino-2,4-dihydroxypyrimidine sulfate (DDP) for 30 min at 60°C and stopped with 0.01 M citric acid (pH 6.0). Twenty μL of the derivative samples was injected into FD-HPLC, and the flow rate was 0.7 mL/min. The derivatized methylglyoxal was separated with a mobile phase (0.01 M citric acid buffer (pH 6.0)/MeCN = 97/3) using an ODS column (250 × 4.6 mm, 5 μm particle size; Biosil Chemical Co. Ltd., Taipei, Taiwan) at 33°C. These fractions were measured at an emission of 500 nm with an excitation of 330 nm. The amount of urinary methylglyoxal was defined as level of methylglyoxal × 12 h-urinary volume.

Determination of urinary amount of D-lactate {#sec013}
--------------------------------------------

### Preparation of urine sample {#sec014}

Urinary D-lactate amount from all of the mice were determined. The column-switching FD-HPLC system was used to determine the levels of urinary D-lactate \[[@pone.0227838.ref019], [@pone.0227838.ref026], [@pone.0227838.ref027]\]. Twenty microliter of all urine samples were mixed with 10 μL of propionic acid (as the internal standard \[I.S.\]) and 170 μL of MeCN before configuration (700 g, 10 min, 4°C). Then, 100 μL of sample supernatants were derivatized with 100 μL of 8 mM 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ) in MeCN, 25 μL of 280 mM 2,2'-dipyridyl disulfide (DPDS) in MeCN, and 25 μL of 280 mM triphenylphosphine (TPP) in MeCN at 30°C for 3 h. Finally, the reaction was stopped with 250 μL of 0.1% TFA~(aq)~, and the derivatives were purified via passing through the MonoSpin^™^ SCX cartridge (GL Science Inc., Tokyo, Japan).

### Separation of lactate {#sec015}

The urinary lactate derivatives were separated with the mobile phase (H~2~O/MeCN/methanol/ = 68/12/20) using an Aqu-ODS-W-5u column (250 × 4.6 mm, 5 μm particle size; Biosil Chemical Co. Ltd, Taipei, Taiwan) at 30°C. The flow rate was set 0.7 mL/min for 0--35 min and 0.9 mL/min for 35.1--60 min \[[@pone.0227838.ref019], [@pone.0227838.ref027]\]. The amount of urinary lactate was defined as lactate levels ×12 h urinary volume.

### Enantiomeric separation of D-lactate {#sec016}

The fraction of lactate derivatives was collected and introduced into a Chiralpak AD‐RH column (150 × 4.6 mm, 5 μm particle size; Daicel Co. Osaka, Japan) with the mobile phase (H~2~O/MeCN = 40/60) at a flow rate of 0.3 mL/min. Both the total lactate and D-lactate levels were determined according to the areas of the corresponding peaks on the chromatograms (D-7500 integrator; Hitachi, Tokyo, Japan). The derivatives were detected at an emission wavelength of 547 nm with an excitation of 491 nm \[[@pone.0227838.ref019], [@pone.0227838.ref027]\]. Urinary D-lactate amount were defined as levels of D-lactate ×12 h urinary volume.

Statistical analysis {#sec017}
--------------------

The results are expressed as means ± standard deviation. The significant difference in means was determined using the Kruskal-Wallis test for nonparametric statistics; *p*‐values less than 0.05 was taken to indicate statistical significance. All of the data analysis was performed using Statistical Product and Service Solutions (SPSS) for Windows 19^th^ version (IBM, IL, USA).

Results {#sec018}
=======

Biochemical assays {#sec019}
------------------

There were no significant differences at baseline in NAG (N \[1.93 ± 0.15 U/L\] *vs*. AA \[1.92 ± 0.12 U/L\] *vs*. AA+P \[1.95 ± 0.10 U/L\]) and urinary protein (N \[1.21 ± 0.34 mg/day\] *vs*. AA \[1.17 ± 0.29 mg/day\] *vs*. AA+P \[1.26 ± 0.34 mg/day\]) among the three groups. BUN (20.67 ± 0.73 *vs*. 23.00 ± 2.09 mg/dL, *p* \< 0.05), Scr (0.27 ± 0.04 *vs*. 0.36 ± 0.06 mg/dL, *p* \< 0.05), NAG (2.22 ± 0.42 *vs*. 2.94 ± 0.13 U/L, *p* \< 0.05), and urinary protein (1.75 ± 0.68 *vs*. 2.94 ± 0.09 mg/day, *p* \< 0.05) in the AA+P group were significant lower in the AA group on day 14 ([Table 1](#pone.0227838.t001){ref-type="table"}).

10.1371/journal.pone.0227838.t001

###### Biochemical parameters of normal (N), aristocholochic acid (AA), and aristocholochic acid + prednisolone (AA+P) groups.

![](pone.0227838.t001){#pone.0227838.t001g}

  Group   NAG (μM/min/L)   UP (mg/day)                                          BUN (mg/dL)   Scr (mg/dL)                                                                                                
  ------- ---------------- ---------------------------------------------------- ------------- ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------
  N       1.93 ± 0.15      1.93 ± 0.06[\*\*](#t001fn003){ref-type="table-fn"}   1.21 ± 0.34   1.26 ± 0.20[\*\*](#t001fn003){ref-type="table-fn"}   17.85 ± 1.91[\*\*](#t001fn003){ref-type="table-fn"}   0.22 ± 0.07[\*\*](#t001fn003){ref-type="table-fn"}
  AA      1.92 ± 0.12      2.94 ± 0.13                                          1.17 ± 0.29   2.94 ± 0.09                                          23.00 ± 2.09                                          0.36 ± 0.06
  AA+P    1.95 ± 0.10      2.22 ± 0.42[\*](#t001fn002){ref-type="table-fn"}     1.26 ± 0.34   1.75 ± 0.68[\*](#t001fn002){ref-type="table-fn"}     20.67 ± 0.73[\*](#t001fn002){ref-type="table-fn"}     0.27 ± 0.04[\*](#t001fn002){ref-type="table-fn"}

There were no significant difference of NAG and UP among N, AA, and AA+P groups at baseline. The BUN, Scr, NAG activity, and UP excretion of N and AA+P group mice significantly decreased on day 14 compared with those of AA-group mice. Baseline was defined as the day at the beginning of experiment (before the mice were administrated AA). N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone; NAG, *N*-acetyl-β-D-glucosamine; BUN, blood urea nitrogen; Scr, serum creatinine; UP, urinary protein.

\**p* \< 0.05

\*\* *p* \< 0.01 significantly different from the AA group.

Histological examination {#sec020}
------------------------

Sections stained with PAS in AA-group exhibited pathological damage, including cell infiltration, tubular cell atrophy, and interstitial fibrosis, but those in AA+P group exhibited alleviation. THIS of AA-group (7.34 ± 0.89) was significantly higher than those of N (0.36 ± 0.16), and AA+P-group (2.99 ± 0.89) on day 14 ([Fig 2](#pone.0227838.g002){ref-type="fig"}). The histological examination for the Trichrome indicated collagen deposition in the AA group (13.19 ± 1.96%) was significantly higher than that of the mice in the N (6.31 ± 0.26%) and AA+P groups (9.05 ± 1.24%) (*p* \< 0.05) ([Fig 3](#pone.0227838.g003){ref-type="fig"}).

![Periodic acid-Schiff (PAS) staining and tubulointerstitial histological score (TIHS) of kidney on day 14.\
There was generally no damage in the renal cortex of normal-group (N) mice (A). Moderate tubulointerstitial damage existed in the renal cortex of AA-group mice (B). AA+P group mice demonstrated amelioration of tubulointerstitial damage (C). (Periodic acid-Schiff \[PAS\] stain, 200× magnification). The tubulointerstitial histological scores (TIHS, including cell infiltration, tubular atrophy, and interstitial fibrosis) of mice in the AA group were significantly higher than those of mice in the normal and AA+P groups on day 14 (D). N, normal group; AA, aristolochic acid group; AA+P: AA+P: aristolochic acid + prednisolone.Δ indicates cell infiltration; **→** indicates interstitial fibrosis; \# indicates tubular atrophy. \**p* \< 0.05, \*\**p* \< 0.01 significantly different from the AA group; \# *p* \< 0.05, \#\# *p* \< 0.01 significantly different from the N group.](pone.0227838.g002){#pone.0227838.g002}

![Masson's trichrome staining and semi-quantification of collagen deposition on day 14.\
Collagen deposition in AA-group mice (B) was more severe than that in AA+P-group mice (C). There was almost no collagen deposition in N-group mice (A). The area of fibrosis was assessed based on the blue coloration in the AA group was higher than that in the N and AA+P groups (D). N, normal group; AA, aristolochic acid group; AA+P: AA+P: aristolochic acid + prednisolone. **→** indicates interstitial fibrosis. \* *p* \< 0.05 significantly different from the AA group; \# *p* \< 0.05 significantly different from the N group.](pone.0227838.g003){#pone.0227838.g003}

Immunofluorescence study {#sec021}
------------------------

The semi-quantification scores of TGF-β (N \[0.35 ± 0.37\] *vs*. AA \[6.88 ± 1.18\] *vs*. AA+P \[2.67 ± 0.57\]) were significantly decreased (*p* \< 0.05); those of MMP-9 (N \[0.63 ± 0.42\] *vs*. AA \[3.43 ± 1.36\] *vs*. AA+P \[11.20 ± 0.84\]) and HGF (N \[0.23 ± 0.51\] *vs*. AA \[2.81 ± 0.83\] *vs*. AA+P \[5.79 ± 0.79\]) increased in the N and AA+P groups on day 14 (*p* \< 0.05) ([Fig 4](#pone.0227838.g004){ref-type="fig"}).

![Immunofluorescence staining and semi-quantification in the tubular interstitium on day 14.\
Confocal images (A--I) reveal a red color that demonstrates the deposition of TGF-β (A, D, G), MMP-9 (B, E, H), and HGF (C, F, I) in the N, AA, and AA+P groups, respectively. The expression of TGF-β showed amelioration in AA+P-group mice (G) compared with mice in the AA group (D). The fluorescence intensity of MMP-9 (H) and HGF (I) were significantly increased in AA+P-group mice compared with those in the AA group (E, F). The relative fluorescence intensity of TGF-β, MMP-9, and HGF was semi-quantified (J). The expressions of TGF-β (A), MMP-9 (B), and HGF (C) in the N group were the lowest among the three groups. N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone. TGF‐β, transforming growth factor‐β; MMP‐9, matrix metallopeptidase 9; HGF, hepatocyte growth factor. \* *p* \< 0.05, \*\* *p* \< 0.01 significantly different from the AA group; \# *p* \< 0.05, \#\# *p* \< 0.01 significantly different from the N group.](pone.0227838.g004){#pone.0227838.g004}

Separation and identification of altered proteins {#sec022}
-------------------------------------------------

There were 47 altered peaks among the N, AA, and AA+P groups on day 14 ([Fig 5](#pone.0227838.g005){ref-type="fig"}), which were identified according to the MASCOT analysis included 39 proteins, including glycolysis, anti-oxidation, ATP synthesis, and apoptosis-related proteins, etc. The amplified chromatograms of [Fig 5](#pone.0227838.g005){ref-type="fig"} ([S1 Fig](#pone.0227838.s004){ref-type="supplementary-material"}) and all the altered proteins ([S2 Table](#pone.0227838.s002){ref-type="supplementary-material"}) can be found in supporting information. All of the chromatograms of each group were shown in [S2 Fig](#pone.0227838.s005){ref-type="supplementary-material"}. Most of the glycolysis-related proteins in the AA+P group were lower than those in the AA group. These glycolysis-related proteins included fructose-bisphosphate aldolase B (aldolase B), glyoxalase 1 (GLO1), pyruvate dehydrogenase E1 α 1 (PDH E1 α 1), M2-type pyruvate kinase (PKM2), triosephosphate isomerase (TPI), phosphoglycerate kinase (PGK) and aldose reductase (AR) ([Table 2](#pone.0227838.t002){ref-type="table"}). The expression of altered protein was shown in [Fig 6](#pone.0227838.g006){ref-type="fig"}.

![Chromatograms of proteins in the kidneys of mice derivatized with DAABD-Cl on day 14.\
The lower, middle, and upper chromatograms were obtained from the kidney homogenates of normal- (red), AA- (green), and AA+P- (blue) group mice, respectively. The 47 altered peaks among three groups were numbered. N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone; DAABD-Cl, 7-chloro-*N*-\[2-(dimethylamino)ethyl\]-2,1,3-benzoxadiazole- 4-sulfonamide.](pone.0227838.g005){#pone.0227838.g005}

![Altered peak heights corresponding to the glycolysis-related proteins.\
The altered peak no. 22, 28 and 32 were compared in [Fig 4](#pone.0227838.g004){ref-type="fig"} and identified glycolysis-related proteins by MASCOT. Peak numbers are the same as in [Table 1](#pone.0227838.t001){ref-type="table"}. Aldolase B: fructose-bisphosphate aldolase B; GLO1: glyoxalase 1; PDH E1 α 1: pyruvate dehydrogenase E1 α 1; PKM2: M2-type pyruvate kinase; TPI: triosephosphate isomerase; PGK: phosphoglycerate kinase; AR: aldose reductase. \* *p* \< 0.05 significantly different from the AA group; \# *p* \< 0.05 significantly different from the N group.](pone.0227838.g006){#pone.0227838.g006}

10.1371/journal.pone.0227838.t002

###### Comparison of glycolysis-related proteins among the N, AA, and AA+P groups on day 14.

![](pone.0227838.t002){#pone.0227838.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peak\                                          N: AA: AA+P\                                                                                 Protein                            Molecular mass (Da)   GI number
  number[^a^](#t002fn001){ref-type="table-fn"}   (Ratio)                                                                                                                                               
  ---------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------- --------------------- --------------
  22                                             1: 6.56[^\#^](#t002fn005){ref-type="table-fn"}: 0.87[\*](#t002fn004){ref-type="table-fn"}    Fructose-bisphosphate aldolase B   39,548                gi\|15723268

  22                                             1: 6.56[^\#^](#t002fn005){ref-type="table-fn"}: 0.87[\*](#t002fn004){ref-type="table-fn"}    Glyoxalase 1                       20,826                gi\|19354350

  22                                             1: 6.56[^\#^](#t002fn005){ref-type="table-fn"}: 0.87[\*](#t002fn004){ref-type="table-fn"}    Pyruvate dehydrogenase E1 α 1      43,204                gi\|6679261

  28                                             1: 13.40[^\#^](#t002fn005){ref-type="table-fn"}: 4.06                                        M2-type pyruvate kinase            57,878                gi\|1405933

  32                                             1: 39.00[^\#^](#t002fn005){ref-type="table-fn"}: 1.85[\*](#t002fn004){ref-type="table-fn"}   Triosephosphate isomerase          26,679                gi\|54855

  32                                             1: 39.00[^\#^](#t002fn005){ref-type="table-fn"}: 1.85[\*](#t002fn004){ref-type="table-fn"}   Phosphoglycerate kinase            59,716                gi\|6679937

  32                                             1: 39.00[^\#^](#t002fn005){ref-type="table-fn"}: 1.85[\*](#t002fn004){ref-type="table-fn"}   Aldose reductase                   35,725                gi\|786001
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^The peak numbers correspond to those shown in [Fig 4](#pone.0227838.g004){ref-type="fig"}.

^b^The ratio of AA or AA+P groups to N group is listed in the table; the intensity of the N group was set at 1.

^c^NCBI processed each consecutive sequence record as GI number, a simple series of digits. N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone.

\**p* \< 0.05, significantly different from the AA group

\# *p* \< 0.05, significantly different from the N group.

Immunoblotting analysis {#sec023}
-----------------------

The differences in GLO1, aldolase B, and TPI expressions were similar among the three groups ([Fig 7A, 7B and 7C](#pone.0227838.g007){ref-type="fig"}). On day 14, the GLO1 protein expression in the kidney homogenate of the N (100.0 ± 30.9%) and AA+P (108.9 ± 10.7%) groups were significantly lower than those of the AA group (191.60 ± 61.1%) (*p* \< 0.05) ([Fig 7D](#pone.0227838.g007){ref-type="fig"}), which were similar to the FD‐LC-MS/MS proteomics findings. Moreover, aldolase B protein expression in the kidney homogenate of the N (100 ± 36.3%) and AA+P (136.2 ± 54.7%) groups were significantly lower than those of the AA group (223.6 ± 52.5%) (*p*\< 0.05) as shown in [Fig 7E](#pone.0227838.g007){ref-type="fig"}.TPI protein expression in the kidney homogenate of the N (100.0 ± 19.6%) and AA+P (121.4 ± 9.3%) groups were significantly lower than those of the AA group (181.5 ±25.9%) (*p* \< 0.05) ([Fig 7F](#pone.0227838.g007){ref-type="fig"}). All the immunoblotting were shown in [S3 Fig](#pone.0227838.s006){ref-type="supplementary-material"}.

![Immunoblotting analysis of GLO1, aldolase B, and TPI in kidney homogenates on day 14.\
Expression of GLO1 (A), aldolase B (B), and TPI (C) among the three groups on day 14. The β‐actin was used as the internal standard. Semi-quantitation of the relative GLO1 (D), aldolase B (E), and TPI (F) level. The expression of relative GLO1, aldolase B, and TPI level decreased in the AA+P group compared with the AA group. N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone; GLO1, glyoxalase 1; aldolase B,fructose-bisphosphate aldolase B;TPI, triosephosphate isomerase. \* *p* \< 0.05 significantly different from the AA group; \# *p* \< 0.05 significantly different from the N group.](pone.0227838.g007){#pone.0227838.g007}

Amount of methylglyoxal in urine {#sec024}
--------------------------------

The amount of urinary methylglyoxal in the AA (3.413 ± 0.596 μg) and AA+P (3.362 ± 1.049 μg) groups were significantly higher than those in the N group (1.561 ± 0.752 μg) on day 0, but those in both N (1.878 ± 0.396 μg) and AA+P (2.004 ± 0.301 μg) groups were significantly lower than those in the AA group (2.741 ± 0.630 μg) on day 14 (*p* \< 0.05) ([Fig 8](#pone.0227838.g008){ref-type="fig"}).

![The amount of methylglyoxal in the urine on days 0 and 14.\
The amount of urinary methylglyoxal in the N group was lower than that in the AA group on days 0 and 14. There was no significance in the amount of urinary methylglyoxal between the AA and AA+P groups on day 0, but the amount of urinary methylglyoxal in the AA+P group was significantly lower than that in the AA group on day 14. N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone. \* *p* \< 0.05, \*\* *p* \< 0.01 significantly different from the AA group; \# *p* \< 0.05, \#\# *p* \< 0.01 significantly different from the N group.](pone.0227838.g008){#pone.0227838.g008}

Amount of total and D-lactate in urine {#sec025}
--------------------------------------

The amount of urinary total lactate in AA (1.032 ± 0.245 and 0.873 ± 0.322 mmol) and AA+P (1.008 ± 0.307 and 0.756 ± 0.278 mmol) were significantly higher than that in the N group (0.250 ± 0.086 and 0.429 ± 0.147 mmol) on day 0 and 14 (*p* \< 0.05) ([Fig 8](#pone.0227838.g008){ref-type="fig"}). Moreover, the amount of urinary D-lactate in AA (105.7 ± 47.4 μmol) and AA+P (129.9 ± 31.2 μmol) were significantly higher than that in the N (3.557 ± 2.370 μmol) group on day 0 (*p* \< 0.05); but the amount of urinary D-lactate in the N (10.10 ± 5.84 μmol) and AA+P (54.07 ± 5.45 μmol) groups were significantly lower than those in the AA group (86.09 ± 8.44 μmol) on day 14 ([Fig 9](#pone.0227838.g009){ref-type="fig"}).

![The amount of total lactate and D-lactate in the urine on days 0 and 14.\
The chromatograph of total lactate separation on days 0 (A) and 14 (C). The chromatograph of D-lactate separation on days 0 (B) and 14 (D). The amount of urinary total lactate in the N group was lower than that in the AA and AA+P groups, and there was no significance between the AA and AA+P groups on days 0 or 14 (E). The amount of urinary D-lactate in the N group was lower than that in the AA and AA+P groups on days 0 and 14. There was no significance in the amount of urinary D-lactate between the AA and AA+P groups on day 0, but the amount of urinary D-lactate in the AA+P group was significantly lower than that in the AA group on day 14 (g). N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid + prednisolone. \* *p* \< 0.05, \*\* *p* \< 0.01 significantly different from the AA group; \# *p* \< 0.05, \#\# *p* \< 0.01 significantly different from the N group.](pone.0227838.g009){#pone.0227838.g009}

Discussion {#sec026}
==========

Tubulointerstitial injury, such as interstitial renal fibrosis, tubular cell atrophy, and cell infiltration, was truly induced via administration of AA-distilled water for 56 days as noted in the previous findings \[[@pone.0227838.ref018]\]. After chronic inflammation, macrophage accumulation leads to fibrosis via activation of the fibrosis-related myofibroblasts which release extracellular matrix to repair the damage tissue. These histological results differed from the findings in other acute model which was acute tubular necrosis caused by short-term administration of high-dose AA (5--10 mg/kg/day) \[[@pone.0227838.ref019], [@pone.0227838.ref020]\]. However, the long-term use of low-dose AA induces interstitial renal fibrosis, which is similar to human AAN as noted in the first AAN report \[[@pone.0227838.ref001]\].

Consistent with the finding by Vanherweghem *et al*., this study also demonstrated the efficacy of prednisolone for AAN, which supported by improvement of tubular damage and collagen deposition, as well as immune markers (decreased in TGF-β expression and increased HGF and MMP-9 expression). In order to explore prednisolone-induced proteins, this study was the first research to use the proteomics study with FD-LC-MS/MS method to screen proteins after prednisolone treatment, demonstrating that most of the glycolysis-related proteins increased in the AA group and decreased in the AA+P group. Expression of ATP-related proteins also showed similar to glycolysis-related proteins. This might be related to ATP consumption and glycolysis activation due to renal damage and mitochondrial permeability transition pore \[[@pone.0227838.ref020], [@pone.0227838.ref028], [@pone.0227838.ref029]\]. After renal damage, dysfunctions of mitochondrial homeostasis and ATP consumption lead to ATP depletion in acute ischemic kidney injury and diabetic nephropathy \[[@pone.0227838.ref030], [@pone.0227838.ref031]\]. Glycolysis, which harvests energy for repair and regeneration of proximal tubule epithelial cells, are composed of three steps. First, glucose converts into fructose 1,6-bisphosphate via phosphorylation. Moreover, aldose reductase converts some of glucoses into sorbitol which is one of the source of fructose 1,6-bisphosphate \[[@pone.0227838.ref032]\]. Second, fructose 1,6-bisphosphate is cleaved into glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) catalyzing by aldolase B \[[@pone.0227838.ref033]\]. TPI catalyzes the isomerization of DHAP to GAP which is on the direct pathway of glycolysis, and some of DHAP metabolize into methylglyoxal by methylglyoxal synthase \[[@pone.0227838.ref034], [@pone.0227838.ref035]\]. Finally, PGK, pyruvate kinase, and other enzymes successively involve in oxidation of GAP until production of pyruvate and ATP \[[@pone.0227838.ref035], [@pone.0227838.ref036]\]. Moreover, pyruvate dehydrogenase catalyzes pyruvate to acetyl-CoA which enter into Kreb cycle for energy production \[[@pone.0227838.ref037]\].

Several studies have proven the relationship between prednisolone and glucose homeostasis, particularly gluconeogenesis and insulin resistance, but the essential glycolysis-related protein, GLO1, was found in the present study. GLO1 is the enzyme of glyoxalase system which is the major pathway to detoxify methylglyoxal \[[@pone.0227838.ref038]\]. GLO1, the rate-limiting enzyme, spontaneously catalyses the conversion of methylglyoxal-GSH hemithioacetal into thioester *S*-D-lactoylglutathione \[[@pone.0227838.ref039]\]. This step is the most important in metabolism of methylglyoxal into D-lactate \[[@pone.0227838.ref039], [@pone.0227838.ref040]\]. GLO2 metabolizes *S*-D-lactoylglutathione to D-lactate and GSH. The renal protective effect of GLO1 has been proven in different models of kidney injury, and the downregulation of GLO1 expression exacerbates the renal function \[[@pone.0227838.ref041]--[@pone.0227838.ref043]\]. Kumagai *et al*. indicated that the GLO1 protein expression in sham group is similar to those in ischemia/reperfusion injury group in an acute rat model \[[@pone.0227838.ref041]\], but the change of D-lactate has not been determined. However, methylglyoxal, D-lactate, and GLO1 simultaneously increased after 56 days of AA administration in this study. The different findings suggest that the duration of the study period and the severity of tubular injury might impact on GLO1 expression. First, although the mechanism of GLO1 induction is unclear, enzyme induction is a time-consuming process. Second, GLO1, which exists in the cytosol of each cell, might be depleted if the death of tubular epithelial cells occurs during the progression of necrosis.

Methylglyoxal, one of by-products from glycolysis, leads to cell apoptosis and cytotoxicity due to reactive carbonyl groups which reacts with proteins and nucleic acids. These methylglyoxal-adducts are called advanced glycation end products (AGEs) and lose their function \[[@pone.0227838.ref044]--[@pone.0227838.ref046]\]. Several studies have indicated that methylglyoxal and D-lactate increase under condition of renal damage or disease. Thus, the plausible mechanisms of methylglyoxal-exacerbating AAN are noted below. First, the binding of AGEs and its receptors upregulates inflammatory effects via nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) \[[@pone.0227838.ref047]\] and early growth response-1 (Egr-1) \[[@pone.0227838.ref048]\]. Second, methylglyoxal increases oxidative stress, which is assessed via the level of glutathione in the kidneys of mice that received AA due to accumulation of methylglyoxal and *N*^ε^-(carboxymethyl)lysine (CML) \[[@pone.0227838.ref025]\]. Third, methylglyoxal-modified collagen might exacerbate interstitial renal fibrosis via the activation of myofibroblasts \[[@pone.0227838.ref049]\], the inhibition of collagen phagocytosis \[[@pone.0227838.ref050]\], and changes in the structure of the extracellular matrix \[[@pone.0227838.ref051]\].

Conclusion {#sec027}
==========

This study firstly suggested that prednisolone successfully alleviated inflammation and interstitial renal fibrosis and then inhibited glycolysis, which consequently led to reduce methylglyoxal, GLO1, and D-lactate, as well as other glycolysis-related proteins. These findings supported that inhibition of glycolysis might be one of the mechanisms in prednisolone treatment for AAN. These glycolysis parameters (methylglyoxal, GLO1, and D-lactate) increased in the chronic AAN, which were quite different from acute kidney injury model. Since this FD-LC-MS/MS method was indeed helpful for exploring pathological and pharmacological mechanisms, it could be applied to screening disease-related proteins in the future.

Supporting information {#sec028}
======================

###### The gradient elution program of FD‐HPLC conditions for protein separation.

(PDF)

###### 

Click here for additional data file.

###### Altered proteins in the kidney homogenate among three groups on Day14.

^a^The peak numbers correspond to those described in [Fig 3](#pone.0227838.g003){ref-type="fig"}. ^b^The ratio of AA or AA+P groups to N group showed in the table, and the intensity of N group was regarded as "1". ^c^NCBI processed each consecutive sequence record as GI number, a simple series of digits. N, normal group; AA, aristolochic acid group; AA+P: aristolochic acid+prednisolone. \**p* \< 0.05, significantly different from AA group; \# *p* \< 0.05, significantly different from N group.

(PDF)

###### 

Click here for additional data file.

###### Antibody.

(PDF)

###### 

Click here for additional data file.

###### The detailed and amplified chromatograms of [Fig 5](#pone.0227838.g005){ref-type="fig"}.

The lower, middle, and upper chromatograms were obtained from the kidney homogenates of N- (red), AA- (green), and AA+P- (blue) group mice, respectively. The 47 altered peaks among three groups were numbered.

(PDF)

###### 

Click here for additional data file.

###### The chromatograms of FD-HPLC for separating proteins.

AA+P indicated the six chromatograms of AA+P group; AA indicated the six chromatograms of AA group; N indicated the six chromatograms of N group.

(PDF)

###### 

Click here for additional data file.

###### The immunoblotting images for [Fig 7](#pone.0227838.g007){ref-type="fig"}.

\(A\) Both of the partial membranes which blotted GLO1 and β‐actin antibodies were acquired from the same gel. After the proteins of gel were transferred onto the nitrocellulose membrane, the membrane was blocked with 10% skim milk. Before incubated with primary antibodies, the membrane was cut into two parts. One partial membrane was incubated with anti-GLO1 antibody, and another was incubated with anti-β‐actin antibody, respectively. (B) Both of the band of aldolase B and β‐actin were acquired from the same gel and same membrane. (C) Both of the band of TPI and β‐actin were acquired from the same gel and same membrane.

(PDF)

###### 

Click here for additional data file.

###### WB beta-actin.

(TIF)

###### 

Click here for additional data file.

###### WB GLO1.

(TIF)

###### 

Click here for additional data file.

###### WB Aldolase B & beta-actin.

(TIF)

###### 

Click here for additional data file.

###### WB TPI & beta-actin.

(TIF)

###### 

Click here for additional data file.
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The authors investigate here the effect of prednisolone treatment on the protein expression in a mice model of AAN using a proteomics technique. Six-week‐old female C3H/He mice were randomly divided into three groups: normal (N), aristolochic acid (AA), and aristolochic acid + prednisolone (AA+P) groups (n = 10 each group).The aim of the study is to (1) explore the effect of prednisolone on changes in glycolysis-related protein expression using the FD-LC-MS/MS method and (2) to clarify the pharmacological mechanisms of prednisolone in AA model. The authors found that 1) prednisolone improved tubulointerstitial damage; 2) the glycolysis-related protein glyoxalase 1 (GLO1) decreased in the AA+P group; 3) prednisolone decreased the urinary methylglyoxal which was accompanied with decrease in urinary D-lactate. The authors conclude that 1) The renal protective mechanism of Prednisolone might be associated with down-regulation of GLO1 via reducing the contents of methylglyoxal derived from glycolysis; 2) they demonstrated for the first time the biochemical efficacy of prednisolone, and urinary methylglyoxal and its metabolite-D-lactate might be potential biomarkers for AAN.
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5\) Figure 8
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Issues 2: The authors need to add more discussion and background in the introduction part.

Answer:

We have increase the paragraph to introduce the background and discussion in the part of introduction, especially the mechanisms of aristolochic acid-induced cytotoxicity and carcinogenicity from the recent study.

Please use full name in title line.

Answer:

We have revised our title according to your suggestion, so we have changed our title as the following.

Please prepare a figure to illustrate the work-flow for the better understanding.

Answer:

We have prepared a flow chart to explain for our study step by step in Fig 1

Reviewer \#2: COMMENTS TO AUTHORS

(1)As the authors discussed, the fructose 1,6-bisphosphate is cleaved into glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) catalyzing by aldolase B. To demonstrate that Prednisolone inhibited glycolysis, which consequently led to reduce methylglyoxal, GLO1, and D-lactate the authors should also verify by a conventional immunological assay the increase of the Fructose-bisphosphate aldolase B and TPI.

Answer:

Thanks for your suggestion. We have performed the immunoblotting for aldolase B and TPI to confirm protein expression. Moreover, we have acquired the similar results to the proteomics findings. We have added these new findings in the part of "Method and materials" and "Results".

\(2\) Its not clear along all the paper how many samples have been used for the different experiments (i.e, how many samples were used for WB analysis?

Answer:

All mice of biochemical data (including BUN, Scr, urinary protein, and NAG), sections (PAS stain, Masson trichrome stain, and immunofluourance), urinary methylglyoxal, and urinary D-lactate were determined. We selected six mice from each group to perform proteomics study. We selected six mice from each group to perform immunoblotting for glyoxalase1, aldolase B, and triphosphate isomerase because of the rest of the kidney tissue.

\(3\) Figure 4

I think , each group chromatogram should be reported with its proper Fluorescence intensity, otherwise chromatograms comparison is not possible.

Answer:

We have reported the chromatograms according to your suggestion. The chromatograms with the correct scales were shown in Fig 5.

4\) Figure 5

Why did you use peak height instead of peak area to calculate the differences among the 3 different groups of samples? From S1_Fig , peak n. 22 seems higher in Normal (red line) instead of AA (green line); peak n. 28 seems not to be the same in the 3 different chromatograms as well as for peak n.32, which seems to be higher in Normal instead of AA.

Answer:

Usually, peak area is better than peak height. In our case, each peak has different baseline. If we calculated with peak area, the intensity of the peak might include part of other peak area. This FD-LC-MS/MS method used peak height rather than peak area according to the previous study (Ichibangase et al., Journal of Proteome Research; 2007, 6, 2841-2849).

About this question "From S1_Fig , peak n. 22 seems higher in Normal (red line) instead of AA (green line); peak n. 28 seems not to be the same in the 3 different chromatograms as well as for peak n.32, which seems to be higher in Normal instead of AA.", we have labeled peak no.22, 28, and 32 of each chromatogram of sample in each group in S2_Fig. According to the results of S2_Fig, we acquired the intensity and expressed as mean ± SD in Table 2 and Table S2. All of this intensity is not only acquired from S1_Fig. Thus, we average the intensity of six sample data from each group and compared among three groups.

5\) Figure 8

From Figure 8 A it doesn't seem that the amount of urinary total lactate in the N group was lower than that in the AA and AA+P groups, instead it seems that the amount of urinary total lactate in the N group was higher than that in the AA and AA+P groups. Please clarify.

Answer:

Answer: Figure 8 A and 8C indicated the "level" of total lactate according to the chromatograms but not the "amount" of total lactate. Figure 8B and 8D indicated the "level" of D-lactate according to the chromatograms but not the "amount" of D-lactate. The amount of total lactate was expressed as: amount of lactate (mmol) = level of lactate (mM) x urinary volume (µL); Expression of D-lactate was similar to expression of total lactate (amount of D-lactate \[µmol\] = level of lactate \[µM\] x urinary volume \[µL\]). Because the level of lactate is very low, we use the amount which could more reflect how much methyglyoxal metabolize into D-lactate in mouse body.

6\) Table 1

Missing biochemical data at basal (T0) could clarify the differences of the animal groups at the beginning of the study, useful to appreciate and confirm the effect of therap

Answer: We have determined the urinary data (urinary protein and NAG) on baseline according to your suggestion. However, it is not impossible to acquire the blood data on baseline, because it is necessary to acquire more than 60 µL of blood sample so that we could analyze the data. The body weight of mouse is about 20 g, and it is a high stress to get such volume of blood for a mice. We only can get such large volume, when the mouse were sacrificed. In order to solve this problem, we compared blood data of the "normal group" with AA and AA+P groups on day 14.
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